Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Nebulized Long-Acting vs. Short-Acting Bronchodilators in ECOPD
NCT07721922Phase 4Not yet recruiting
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 4 trial of revefenacin, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by University of Tennessee Graduate School of Medicine. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
revefenacinformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07721922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721922.